The Glioblastoma Multiforme Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Download Sample Pages @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight
Glioblastoma Multiforme Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma Multiforme with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Glioblastoma Multiforme Treatment.
-
Glioblastoma Multiforme key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Glioblastoma Multiforme Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Glioblastoma Multiforme market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Glioblastoma Multiforme Therapeutics Landscape
The patients with Glioblastoma Multiforme continue to experience a tremendous burden of treatment and low survival rates. Surgery proves to be a mainstay treatment for Glioblastoma multiforme (GBM). There is a need for developing novel targeted therapies that shall fuel the Glioblastoma multiforme (GBM) market in the coming years.
Some of the key companies in the Glioblastoma Multiforme therapeutics development include:
-
Tocagen
-
Apogenix
-
Bristol-Myers Squibb
-
Ono Pharmaceuticals
-
Johnpro Biotech
-
AbbVie
-
VBL Therapeutics
-
DelMar Pharmaceuticals
-
Celgene
-
Green Cross Cell Corporation
And many others.
Glioblastoma multiforme (GBM) therapies covered in the report include:
-
Immuncell-LC
-
TTAC-000
-
Nivolumab
-
Ipilimumab
-
Asunercept
-
Marizomib
-
Siroquine (JP001)
-
Toca 511 and Toca FC
-
Dianhydrogalactitol (VAL-083)
-
Ofranergene obadenovec (VB-111)
-
Depatuxizumab mafodotin (ABT-414)
And many more.
Request for Sample Pages @ Glioblastoma Multiforme Emerging Therapies and Key Companies
Table of Content
1. Report Introduction
2. Glioblastoma Multiforme
3. Glioblastoma Multiforme Current Treatment Patterns
4. Glioblastoma Multiforme – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Multiforme Late Stage Products (Phase-III)
7. Glioblastoma Multiforme Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Multiforme Discontinued Products
13. Glioblastoma Multiforme Product Profiles
14. Glioblastoma Multiforme Key Companies
15. Glioblastoma Multiforme Key Products
16. Dormant and Discontinued Products
17. Glioblastoma Multiforme Unmet Needs
18. Glioblastoma Multiforme Future Perspectives
19. Glioblastoma Multiforme Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Visit to get the sample report: https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/